The synthesis and structure-activity relationship of decahydroisoquinoline derivatives with various benzoic acid substitutions as GluK1 antagonists are described. Potent and selective antagonists were selected for a tailored prodrug approach in order to facilitate the evaluation of the new compounds in pain models after oral administration. Several diester prodrugs allowed for acceptable amino acid exposure and moderate efficacy in vivo.
Keywords: Decahydroisoquinolines; GluA2; GluK1 antagonists; Pain; Prodrug.
Copyright © 2013 Elsevier Ltd. All rights reserved.